Director Robin Shane Readnour’s related funds sold 16,119 ANTX shares at about $6 on Sept. 3 and 8 under Rule 10b5-1 plans; he still holds 9,077 shares directly.

Director Margaret M. FitzPatrick bought 2,098 AN2 Therapeutics shares at $5.53 on Sept. 1, 2026, raising her direct holdings to 10,708 shares with no 10b5-1 plan.

MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco

MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco